03 August 2018
Visiongain’ has launched a new pharma report Global Pharmacovigilance Market Forecast 2018-2028 : US, Japan, Germany, the UK, France, Italy, Spain, Brazil, Russia, India, China, South Korea, National Pharmacovigilance Systems, Leading Companies, Trends
This report covers trends in the pharmacovigilance market from 2017. It discusses those operations, regulations for drug monitoring, and the future of drug safety. It analyses pharmacovigilance from historical events to the future, predicting how post-marketing drug assessments will develop, and revenues from those services expand. National regulatory authorities are moving towards risk-benefit management planning to assess drug safety, putting greater pressure on pre-marketing safety and efficacy data. Needs for post-marketing surveillance have also increased, with active and intensive monitoring being introduced into adverse drug reaction reporting systems.
The lead analyst of the report commented “Using pharmacogenomics to establish safety profiles for drugs potentially represents the most significant steps in pharmacovigilance over the next decade. The number of clinical genetic tests being designed and produced is increasing, as is the volume of pharmacogenomic data submitted to regulators. As more is understood of the role of genetic variations in drug safety, regulators will demand more pharmacogenomic data during the approval application process for inclusion in risk management strategies.
The discovery and use of biomarkers, either during drug development or the early post-marketing phase, can accelerate drug approval or expansion of approval. New classification methods for adverse reactions will help to establish ADR mechanisms in relation to the genetic characteristic of the patient. This will, in a similar way to the discovery of biomarkers, help mark out subpopulations for whom the drug is an inappropriate. Further development of the system will eventually lead to its adoption as a common method of classification globally.”
Leading companies featured in the report include Accenture PLC, Cognizant Technology Solutions Corporation, Tata Consultancy Services (TCS), Capgemini SE, Tech Mahindra Limited, Infosys Limited (Infosys), Wipro Limited (Wipro), Oracle Corporation (Oracle), Bristol-Myers Squibb Company, HCL Technologies Ltd., Olympus Corporation
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 207 336 6100
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Deviating from protocols raises the danger of missing or delaying data collection from current investigations. This highlights the growing importance of digital medicine, which is being aided by advancements in cloud, mobile, and IoT technology.
11 October 2021
High performance HPC and supercomputing technology have evolved substantially in China in the last decades, leading to extraordinary accomplishments. HPC-based and combined pharmaceutical chemical and computational biology computational discovery and design has become a significant technique in drug research and development and is sponsored financially by the Chinese government.
07 October 2021
Many health-care organizations are seeing organic growth at levels that their supply networks were never designed to handle. Others are frantically attempting to integrate diverse technology and procedures as part of a consolidation effort.
06 October 2021
Rise in prevalence of meningitis, increasing initiatives by government and regulatory authorities coupled strong funding support from non-profit organizations is expected to drive the global meningococcal vaccines market